COVID-19 oral drug significantly reduces infection mortality in the elderly
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
COVID-19 oral drug significantly reduces infection mortality in the elderly
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The Lancet: COVID-19 oral drug significantly reduces infection mortality in the elderly.
On October 8, The Lancet published an article “Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study”, which is the largest real-world study on the effectiveness of two COVID-19 oral drugs in the treatment of Omicron variant strain infection.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
The research data comes from 1,074,856 community-infected patients in Hong Kong in 2022.
After screening, 4,983 molnupiravir users and 5,542 Paxlovid users were included in the statistics, of which 9,176 were older than 60 years old (87.1%) and completed the full course of vaccination. of only 2,650 (22.4%) .
That is to say, most of them belong to the high-risk group of COVID-19 infection – advanced age and unvaccinated.
The study found that the use of two COVID-19 drugs in the early stage of infection can significantly reduce the risk of disease progression and death in the elderly. Among them, the COVID-19 oral drug Paxlovid reduced the risk of death after hospitalization in the elderly by 79%.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
